<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737126</url>
  </required_header>
  <id_info>
    <org_study_id>Endo02</org_study_id>
    <nct_id>NCT00737126</nct_id>
  </id_info>
  <brief_title>The Effect of Folic Acid Administration in the Progression of Microalbuminuria</brief_title>
  <official_title>Folic Acid Administration Reduces the Progression of Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorios Valdecasas S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of diabetic nephropathy has been linked to several genetic polymorphisms,
      including those related with homocysteine metabolism such as the methylenetetrahydrofolate
      reductase (MTHFR)and the cystathionine-beta-synthase genes. Such alterations are associated
      with hyperhomocysteinemia, which is a known independent risk factor for the development of
      endothelial dysfunction and cardiovascular disease.

      In the Mexican population there is a high prevalence of the C677T MTHFR mutation. The
      investigators performed this study to evaluate the prevalence of this polymorphism in type 2
      diabetic patients with diabetic nephropathy compared with type 2 diabetic patients without
      nephropathy, besides evaluating the relationship of hyperhomocysteinemia with endothelial
      dysfunction and microalbuminuria before and after the administration of folic acid. We
      proposed that the endothelial dysfunction caused by the hyperhomocysteinemia could be
      reversed after the administration of folic acid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in albumin excretion rate</measure>
    <time_frame>Four months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum homocysteine, thrombomodulin and von Willebrand factor.</measure>
    <time_frame>Four months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <condition>Hyperhomocysteinemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of an oral placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of oral folic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>Administration of a daily tablet containing 5 mg of folic acid for 4 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of an oral placebo pill</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus patients with 5 to 15 years of diagnosis

          -  Microalbuminuria (defined as a urinary albumin/creatinine ratio between 30 and 300
             mg/g)

          -  A1c less than 9% in the last year

        Exclusion Criteria:

          -  Acute diabetic complications

          -  A1c greater than 9% in the last year

          -  Acute infectious process

          -  Hepatic disease

          -  Thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J Lavalle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Departamento de Endocrinología del Hospital Universitario &quot;José E. González&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;José E. González&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>August 18, 2008</last_update_submitted>
  <last_update_submitted_qc>August 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jesús Zacarías Villarreal Pérez</name_title>
    <organization>Departamento de Endocrinologia</organization>
  </responsible_party>
  <keyword>Diabetic nephropathies</keyword>
  <keyword>Hyperhomocysteinemia</keyword>
  <keyword>Folic acid</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Hyperhomocysteinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

